Notice of Annual General Meeting

RNS Number : 9767B

Redx Pharma plc

07 April 2017

 

7 April 2017

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company")

Notice of Annual General Meeting

Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that its Annual General Meeting will be held at 9.30am on 20 April 2017 at Redx Pharma Plc, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.

Following the announcement of preliminary results for the financial year ended 30 September 2016 on 21 March, the Company announces that the Annual Report and Accounts and notice of Annual General Meeting have now been posted to shareholders. The Annual Report and Accounts is also available to view on Redx's website at www.redxpharma.com.

For further information, please contact:

Redx Pharma Plc
Neil Murray, Chief Executive Officer	T: [phone]
Karl Hård, Head of Investor Relations & Corporate Communications	T: [phone]
Cantor Fitzgerald Europe (Nomad & Broker)	T: [phone]
Phil Davies/ Michael Reynolds
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång/ Chris Lee/ David Wilson
Consilium Strategic Communications	T: [phone]
Amber Fennell/ Matthew Neal/ Melissa Gardiner

About Redx Pharma Plc

Company website: www.redxpharma.com 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, immunology and infection providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

 

END

 

 

NOAKMGGDDNMGNZM